As of May 3, 2024, the HALO stock has a P/E ratio of 18.74. The calculation is based on the latest EPS of $2.13 and the stock price of $39.91 per share. A decrease of 14% has been observed in the PE ratio compared to its average of 21.7 of the past four quarters.
The mean historical PE ratio of Halozyme Therapeutics over the last seven years is 34.61. The current 18.74 price-to-earnings ratio is 46% less than the historical average. Analyzing the last seven years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Mar 2022 quarter saw the lowest point at 12.95, with a price of $39.88 and an EPS of $3.08.
Maximum annual increase: 173.47% in 2022
Maximum annual decrease: -68.73% in 2021
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 17.35 | -54.88% |
| 2022 | 38.45 | 173.47% |
| 2021 | 14.06 | -68.73% |
| 2020 | 44.96 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | 44.04 | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
The current PE ratio of HALO is under its 3, 5 and 10-year averages.
HALO's PE ratio is less than its peer stocks LLY and PFE, but it is above JNJ's and BAX's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BAX Baxter International Inc | 7.05 | $18.8B |
| JNJ Johnson & Johnson | 9.78 | $359.25B |
| HALO Halozyme Therapeutics Inc | 18.74 | $5.06B |
| PFE Pfizer Inc | 73.18 | $157.04B |
| LLY ELI LILLY & Co | 107.77 | $698.52B |
| MNKD Mannkind Corp | N/A | $1.19B |
As of May 3, 2024, HALO stock has a price to earnings ratio of 18.74.
Over the last 3 years, the average PE ratio for HALO stock is 21.52.
Over the last 5 years, the average PE ratio for HALO stock is 33.03.
Over the last seven years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.
HALO's current price to earnings ratio is 46% below its 7-year historical average.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (May 3, 2024), Halozyme Therapeutics's share price is $39.91. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $2.13. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 18.74. PE RATIO(18.74) = STOCK PRICE($39.91) / TTM EPS($2.13)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.